Memory Boost and Cognitive Aging Slowdown with Daily Multivitamin Supplements
A recent study has revealed that the regular intake of a multivitamin may contribute to a significant reduction in cognitive decline associated with aging, potentially delaying this decline by up to two years.
The study, conducted by researchers at Mass General Brigham and published in the American Journal of Clinical Nutrition, focused on individuals aged 60 and above who consumed Centrum Silver multivitamins, noting a slower rate of cognitive decline compared to those who received a placebo.
This research constitutes the third phase of the COcoa Supplement and Multivitamin Outcomes Study (COSMOS), collectively indicating that individuals incorporating a daily multivitamin for a duration of up to three years experienced a noteworthy deceleration in cognitive aging, equivalent to a two-year delay.
Multivitamins Linked to Improved Cognitive Scores
The collective participation in the three studies comprised more than 5,000 volunteers.
The initial two studies conducted assessments of participants through telephone or web interviews spanning a period of two to three years.
The findings indicated that individuals who regularly consumed a daily multivitamin exhibited elevated cognitive test scores compared to those who were administered a placebo.
The latest investigation involved the in-person assessment of approximately 600 individuals. Consistent with the findings from the two preceding studies, researchers observed identical outcomes.
A press release from Mass Brigham stated, “The outcomes derived from this recent publication affirm the persistent and statistically significant advantages of daily multivitamin use over a placebo, specifically in enhancing both memory and global cognition.”
Current Dementia Estimate in Australia Sparks Concern
In a more sobering update, the current estimate indicates that over 421,000 Australians are currently living with various forms of dementia this year.
Without a medical breakthrough, this figure is anticipated to rise to over 812,500 by the year 2054.
Within the younger age demographics, specifically individuals in their 30s, 40s, and 50s, it is projected that nearly 29,000 people are presently affected by young onset dementia, a number expected to almost double by 2054.
This research provides hopeful findings at a critical juncture, especially as the Alzheimer’s Association forecasts that by 2060, the United States is projected to have 13.8 million individuals aged 65 and older grappling with Alzheimer’s dementia, unless there are medical advancements to prevent, slow, or cure Alzheimer’s disease.
